FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.8.7  |  FHIR Version n/a  User: [n/a]

8940801000001103: Re-introduced (qualifier value)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 01-Oct 2007. Module: SNOMED CT United Kingdom drug extension module

Descriptions:

Id Description Lang Type Status Case? Module
40298601000001113 Re-introduced (qualifier value) en Fully specified name Active Only initial character case insensitive SNOMED CT United Kingdom drug extension module
40298701000001115 Re-introduced en Synonym Active Only initial character case insensitive SNOMED CT United Kingdom drug extension module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Re-introduced Is a Non-availability indicator true Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group
Orap 4mg tablets (Eumedica Pharma Ltd) 100 tablet 5 x 20 tablets VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Orap 4mg tablets (Necessity Supplies Ltd) 20 tablet VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Orap 4mg tablets (Waymade Healthcare Plc) 100 tablet VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Orap 4mg tablets (Stephar (U.K.) Ltd) 20 tablet VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Orap 4mg tablets (PI) (Waymade Ltd) 20 tablet VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Dicycloverine 10mg/5ml oral solution (Primegen Ltd) VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Dicycloverine 10mg tablets (Primegen Ltd) VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Dicycloverine 20mg tablets (Primegen Ltd) VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Dicycloverine 10mg/5ml oral solution (Primegen Ltd) 120 ml VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Dicycloverine 10mg tablets (Primegen Ltd) 100 tablet 10 x 10 tablets VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Dicycloverine 20mg tablets (Primegen Ltd) 84 tablet 7 x 12 tablets VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Calcipotriol 50micrograms/g ointment (A A H Pharmaceuticals Ltd) 30 gram VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Artelac Single Dose Unit 0.32% eye drops 0.5ml unit dose (Lexon (UK) Ltd) VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Artelac Single Dose Unit 0.32% eye drops 0.5ml unit dose (Lexon (UK) Ltd) 30 unit dose VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Artelac Single Dose Unit 0.32% eye drops 0.5ml unit dose (Lexon (UK) Ltd) 60 unit dose VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Yemex 25micrograms/hour transdermal patches (Sandoz Ltd) VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Yemex 50micrograms/hour transdermal patches (Sandoz Ltd) VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Yemex 75micrograms/hour transdermal patches (Sandoz Ltd) VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Yemex 100micrograms/hour transdermal patches (Sandoz Ltd) VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Calcort 6mg tablets (Lexon (UK) Ltd) VMP non-availability indicator False Re-introduced Inferred relationship Existential restriction modifier
Yemex 25micrograms/hour transdermal patches (Sandoz Ltd) 5 patch VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Yemex 50micrograms/hour transdermal patches (Sandoz Ltd) 5 patch VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Yemex 75micrograms/hour transdermal patches (Sandoz Ltd) 5 patch VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Yemex 100micrograms/hour transdermal patches (Sandoz Ltd) 5 patch VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Calcort 6mg tablets (Lexon (UK) Ltd) 60 tablet VMP non-availability indicator False Re-introduced Inferred relationship Existential restriction modifier
Levobupivacaine 1.25mg/mL injection solution 200mL bag VMP non-availability indicator False Re-introduced Inferred relationship Existential restriction modifier
Chirocaine 250mg /200ml solution for injection bags (Abbott Laboratories Ltd) VMP non-availability indicator False Re-introduced Inferred relationship Existential restriction modifier
Levobupivacaine 250mg/200ml solution for injection bags 12 bag VMP non-availability indicator False Re-introduced Inferred relationship Existential restriction modifier
Chirocaine 250mg /200ml solution for injection bags (Abbott Laboratories Ltd) 12 bag VMP non-availability indicator False Re-introduced Inferred relationship Existential restriction modifier
Dicycloverine 10mg/5ml oral solution (DE Pharmaceuticals) VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Dicycloverine 10mg tablets (DE Pharmaceuticals) VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Dicycloverine 20mg tablets (DE Pharmaceuticals) VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Fentanyl 25micrograms/hour transdermal patches (DE Pharmaceuticals) VMP non-availability indicator False Re-introduced Inferred relationship Existential restriction modifier
Fentanyl 50micrograms/hour transdermal patches (DE Pharmaceuticals) VMP non-availability indicator False Re-introduced Inferred relationship Existential restriction modifier
Fentanyl 75micrograms/hour transdermal patches (DE Pharmaceuticals) VMP non-availability indicator False Re-introduced Inferred relationship Existential restriction modifier
Fentanyl 100micrograms/hour transdermal patches (DE Pharmaceuticals) VMP non-availability indicator False Re-introduced Inferred relationship Existential restriction modifier
Ramipril 1.25mg capsules (DE Pharmaceuticals) VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Ramipril 2.5mg capsules (DE Pharmaceuticals) VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Ramipril 5mg capsules (DE Pharmaceuticals) VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Dicycloverine 10mg/5ml oral solution (DE Pharmaceuticals) 120 ml VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Dicycloverine 10mg tablets (DE Pharmaceuticals) 100 tablet VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Dicycloverine 20mg tablets (DE Pharmaceuticals) 84 tablet VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Fentanyl 25micrograms/hour transdermal patches (DE Pharmaceuticals) 5 patch VMP non-availability indicator False Re-introduced Inferred relationship Existential restriction modifier
Fentanyl 50micrograms/hour transdermal patches (DE Pharmaceuticals) 5 patch VMP non-availability indicator False Re-introduced Inferred relationship Existential restriction modifier
Fentanyl 75micrograms/hour transdermal patches (DE Pharmaceuticals) 5 patch VMP non-availability indicator False Re-introduced Inferred relationship Existential restriction modifier
Fentanyl 100micrograms/hour transdermal patches (DE Pharmaceuticals) 5 patch VMP non-availability indicator False Re-introduced Inferred relationship Existential restriction modifier
Ramipril 1.25mg capsules (DE Pharmaceuticals) 28 capsule VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Ramipril 2.5mg capsules (DE Pharmaceuticals) 28 capsule VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Ramipril 5mg capsules (DE Pharmaceuticals) 28 capsule VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Potassium phosphate 2mmol/mL injection solution 10mL ampule VMP non-availability indicator False Re-introduced Inferred relationship Existential restriction modifier
Salicylic acid 10% in Emulsifying ointment VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Salicylic acid 10% in Hydrous ointment VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Salicylic acid 10% in White soft paraffin VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Salicylic acid 10% in Yellow soft paraffin VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Potassium phosphate 17.42% (potassium 20mmol/10ml) solution for injection 10ml ampoules (A A H Pharmaceuticals Ltd) VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Salicylic acid 10% in Hydrous ointment (Special Order) VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Salicylic acid 10% in Yellow soft paraffin 1 gram VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Salicylic acid 10% in Yellow soft paraffin 100 gram VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Potassium phosphate 17.42% (potassium 20mmol/10ml) solution for injection 10ml ampoules 10 ampoule VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Potassium phosphate 17.42% (potassium 20mmol/10ml) solution for injection 10ml ampoules (Martindale Pharmaceuticals Ltd) VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Potassium phosphate 17.42% (potassium 20mmol/10ml) solution for injection 10ml ampoules (Unichem Plc) VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Salicylic acid 10% in Emulsifying ointment 1 gram VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Salicylic acid 10% in Emulsifying ointment (Special Order) VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Salicylic acid 10% in White soft paraffin (Special Order) VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Salicylic acid 10% in Emulsifying ointment 100 gram VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Salicylic acid 10% in Hydrous ointment 100 gram VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Salicylic acid 10% in White soft paraffin 1 gram VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Potassium phosphate 17.42% (potassium 20mmol/10ml) solution for infusion 10ml ampoules (Special Order) VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Salicylic acid 10% in Hydrous ointment 1 gram VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Salicylic acid 10% in Yellow soft paraffin (Special Order) VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Salicylic acid 10% in White soft paraffin 100 gram VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Salicylic acid 10% in White soft paraffin 50 gram VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Potassium phosphate 17.42% (potassium 20mmol/10ml) solution for infusion 10ml ampoules 1 ampoule VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Potassium phosphate 17.42% (potassium 20mmol/10ml) solution for injection 10ml ampoules (Unichem Plc) 10 ampoule VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Salicylic acid 10% in White soft paraffin (Special Order) 1 gram VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Salicylic acid 10% in Emulsifying ointment (Special Order) 100 gram VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Salicylic acid 10% in White soft paraffin (Special Order) 100 gram VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Salicylic acid 10% in White soft paraffin (Special Order) 50 gram VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Salicylic acid 10% in Emulsifying ointment (Special Order) 1 gram VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Salicylic acid 10% in Yellow soft paraffin (Special Order) 100 gram VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Potassium phosphate 17.42% (potassium 20mmol/10ml) solution for injection 10ml ampoules (A A H Pharmaceuticals Ltd) 10 ampoule VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Potassium phosphate 17.42% (potassium 20mmol/10ml) solution for infusion 10ml ampoules (Special Order) 10 ampoule VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Potassium phosphate 17.42% (potassium 20mmol/10ml) solution for injection 10ml ampoules (Martindale Pharmaceuticals Ltd) 10 ampoule VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Salicylic acid 10% in Hydrous ointment (Special Order) 1 gram VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Salicylic acid 10% in Hydrous ointment (Drug Tariff Special Order) 100 gram VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Potassium phosphate 17.42% (potassium 20mmol/10ml) solution for infusion 10ml ampoules (Special Order) 1 ampoule VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Salicylic acid 10% in Yellow soft paraffin (Special Order) 1 gram VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Esomeprazole 20mg gastro-resistant capsules (Mawdsley-Brooks & Company Ltd) VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Calcipotriol 50micrograms/g ointment (DE Pharmaceuticals) VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Esomeprazole 20mg gastro-resistant capsules (Mawdsley-Brooks & Company Ltd) 28 capsule VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Calcipotriol 50micrograms/g ointment (DE Pharmaceuticals) 30 gram VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Dovobet ointment (Waymade Healthcare Plc) 30 gram VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Calcort 6mg tablets (Waymade Healthcare Plc) VMP non-availability indicator False Re-introduced Inferred relationship Existential restriction modifier
Tetracosactide 1mg/1ml suspension for injection ampoules 1 ampoule VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Tetracosactide 250micrograms/1ml solution for injection ampoules 1 ampoule VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Artelac Single Dose Unit 0.32% eye drops 0.5ml unit dose (Waymade Healthcare Plc) 60 unit dose VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Calcort 6mg tablets (Waymade Healthcare Plc) 60 tablet VMP non-availability indicator False Re-introduced Inferred relationship Existential restriction modifier
Synacthen 250micrograms/1ml solution for injection ampoules (Atnahs Pharma UK Ltd) 1 ampoule VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Synacthen Depot 1mg/1ml suspension for injection ampoules (Atnahs Pharma UK Ltd) 1 ampoule VMP non-availability indicator True Re-introduced Inferred relationship Existential restriction modifier
Vapor-permeable adhesive film dressing 10cm x 14cm VMP non-availability indicator False Re-introduced Inferred relationship Existential restriction modifier
Vapour-permeable adhesive film dressing 10cm x 14cm 50 dressing VMP non-availability indicator False Re-introduced Inferred relationship Existential restriction modifier

Start Previous Page 65 of 86 Next End

This concept is not in any reference sets

Back to Start